• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PIMASERTIB Drug Record

  • Summary
  • Interactions
  • Claims
  • PIMASERTIB chembl:CHEMBL2107832 Antineoplastic

    Alternate Names:

    PIMASERTIB
    EMD-1036239
    AS703026
    MSC-1936369B
    AS-703026
    EMD 1036239
    AS 703026
    G-02443714
    MSC1936369A
    MSC1936369A; AS703026; EMD 1036239
    MSC-1936369A

    Drug Info:

    Drug Class Kinase Inhibitors
    (3 More Sources)

    Publications:

    Martinelli et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int. J. Cancer
    Vena et al., 2015, The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)., Clin. Cancer Res.
  • PIMASERTIB   NF1

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • PIMASERTIB   MAP2K2

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions

  • PIMASERTIB   MAP2K1

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions

  • PIMASERTIB   NRAS

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Everolimus + Pimasertib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    23629727


    Sources:
    JAX-CKB

  • PIMASERTIB   BRAF

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pimasertib + Sorafenib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    23629727


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • PIMASERTIB   KRAS

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pimasertib + Gemcitabine
    Indication/Tumor Type pancreatic cancer
    Response Type sensitive

    PMIDs:
    23629727 26228206


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • PIMASERTIB   PIK3CA

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Everolimus + Pimasertib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    23629727


    Sources:
    JAX-CKB

  • PIMASERTIB   EGFR

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pimasertib + BEZ235
    Approval Status Preclinical - Cell line xenograft
    combination therapy Pimasertib + Sorafenib

    PMIDs:
    23629727


    Sources:
    JAX-CKB

  • PIMASERTIB   TP53

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pimasertib + Gemcitabine
    Indication/Tumor Type pancreatic cancer
    Response Type sensitive

    PMIDs:
    26228206


    Sources:
    JAX-CKB

  • MyCancerGenome: PIMASERTIB

    • Version: 20-Jun-2017

    Alternate Names:
    MSC1936369B Development Name
    PIMASERTIB Generic Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • JAX-CKB: Pimasertib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Martinelli et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int. J. Cancer
    Vena et al., 2015, The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)., Clin. Cancer Res.

  • TALC: PIMASERTIB

    • Version: 12-May-2016

    Alternate Names:
    PIMASERTIB Primary Drug Name
    PIMASERTIB Drug Generic Name
    MSC1936369B Drug Synonym

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL2107832

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: PIMASERTIB

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL2107832

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: PIMASERTIB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21